Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal-Reference-Cited by-同舟云学术

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Published:2022-07-08 Issue:9 Volume:40 Page:851-861
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Otten Thomas^ORCID,Riemsma Rob,Wijnen Ben,Armstrong Nigel,Stirk Lisa,Gordon Caroline,Ramaekers Bram,Kleijnen Jos,Joore Manuela,Grimm Sabine

Funder

National Institute for Health Research

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-022-01166-2.pdf

Reference27 articles.

1. National Institute for Health and Care Excellence. Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397) [ID1591]: Committee Papers. London: NICE; 2021.

2. National Institute for Health and Care Excellence. Final appraisal document: Belimumab for treating active autoantibody positive systemic lupus erythematosus. London: NICE; 2021.

3. National Institute for Health and Care Excellence. Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397): Final scope. London: NICE; 2020.

4. National Institute for Health and Care Excellence. Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397) [ID1591]. London: NICE; 2016.

5. GlaxoSmithKline. Belimumab for treating active autoantibody-positive systemic lupus erythematosus [ID1591] – Response to request for clarification from the ERG: GlaxoSmithKline; 2020.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal;PharmacoEconomics;2023-09-04